Proper diagnostic distinction of bone marrow failure syndromes can often be challenging. In
particular, for older patients with idiopathic aplastic anemia (AA), differential diagnosis …

Revisiting erythroleukemia : Current Opinion in Hematology Revisiting erythroleukemia :
Current Opinion in Hematology Log in or Register Subscribe to journalSubscribe Get new …

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis.
The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating …

Abstract The Revised International Prognostic Scoring System (IPSS‐R) has been
recognized as the score with the best outcome prediction capability in MDS, but this brought …

Abstract Wilms tumor gene 1 (WT1) is highly expressed in myelodysplastic syndrome (MDS)
cells and is known to reflect the tumor burden in MDS. We evaluated the usefulness of WT1 …

Objectives To ascertain the relevance of bone marrow cellularity (BMC) to the interpretation
of blast percentage (blast%) in MDS prognostication. Methods We compared survival …

Abstract The International Prognostic Scoring System and its revised form (IPSS‐R) are the
most widely used indices for prognostic assessment of patients with myelodysplastic …

Background Myelodysplastic syndromes (MDS) are a group of clonal neoplasms
characterized by ineffective hematopoiesis. Hypomethylating agent (HMA) therapy is one of …

Background Lymphoid aggregates (LA) are occasionally seen in bone marrow biopsies
(BMB) of myelodysplastic syndromes (MDS) patients. Our aim was to evaluate their …

Dear Editor, The proportion of myeloblasts in the bone marrow of patients with
myelodysplastic syndromes (MDS) is an independent prognostic factor, and estimation of …